Angela Nelms - RenovoRx Chief Officer
| RNXT Stock | USD 1.37 0.02 1.48% |
Insider
Angela Nelms is Chief Officer of RenovoRx
| Age | 47 |
| Address | 4546 El Camino Real, Los Altos, CA, United States, 94022 |
| Phone | 650 284 4433 |
| Web | https://renovorx.com |
Angela Nelms Latest Insider Activity
Tracking and analyzing the buying and selling activities of Angela Nelms against RenovoRx stock is an integral part of due diligence when investing in RenovoRx. Angela Nelms insider activity provides valuable insight into whether RenovoRx is net buyers or sellers over its current business cycle. Note, RenovoRx insiders must abide by specific rules, including filing SEC forms every time they buy or sell RenovoRx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Angela Nelms over six months ago Purchase by Angela Nelms of 300 shares of RenovoRx | ||
Angela Nelms over a year ago Acquisition by Angela Nelms of 32500 shares of RenovoRx subject to Rule 16b-3 |
RenovoRx Management Efficiency
The company has return on total asset (ROA) of (1.4187) % which means that it has lost $1.4187 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2057) %, meaning that it created substantial loss on money invested by shareholders. RenovoRx's management efficiency ratios could be used to measure how well RenovoRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.58 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.63). At this time, RenovoRx's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 4.7 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.4 M in 2024.Similar Executives
| Found 12 records | INSIDER Age | ||
| Joan JD | Pharvaris BV | 60 | |
| Jochen Knolle | Pharvaris BV | 74 | |
| Maryann Cimino | Pharvaris BV | N/A | |
| Anne Lesage | Pharvaris BV | 63 | |
| Peng MD | Pharvaris BV | 46 | |
| CPA MBA | Pharvaris BV | 63 | |
| Morgan Conn | Pharvaris BV | 55 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 59 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Annick Deschoolmeester | Pharvaris BV | 51 | |
| RA MSc | Pharvaris BV | 43 | |
| Wim Souverijns | Pharvaris BV | 53 | |
Management Performance
| Return On Equity | -3.21 | ||||
| Return On Asset | -1.42 |
RenovoRx Leadership Team
Elected by the shareholders, the RenovoRx's board of directors comprises two types of representatives: RenovoRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RenovoRx. The board's role is to monitor RenovoRx's management team and ensure that shareholders' interests are well served. RenovoRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RenovoRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ronald CPA, VP Controller | ||
| James Ahlers, Chief Officer | ||
| Leesa Gentry, Senior Operations | ||
| Angela Nelms, Chief Officer | ||
| Ramtin MD, Chairman Founder | ||
| CGMA CPA, Controller VP | ||
| Shaun Bagai, CEO Director |
RenovoRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RenovoRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.21 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | 28.43 M | ||||
| Shares Outstanding | 23.95 M | ||||
| Shares Owned By Insiders | 6.01 % | ||||
| Shares Owned By Institutions | 1.37 % | ||||
| Number Of Shares Shorted | 61.57 K | ||||
| Price To Book | 3,365 X | ||||
| EBITDA | (11.4 M) | ||||
| Net Income | (10.23 M) |
Pair Trading with RenovoRx
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if RenovoRx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RenovoRx will appreciate offsetting losses from the drop in the long position's value.Moving together with RenovoRx Stock
| 0.76 | A | Agilent Technologies Earnings Call Today | PairCorr |
Moving against RenovoRx Stock
| 0.69 | RZLT | Rezolute Fiscal Year End 12th of September 2024 | PairCorr |
| 0.37 | LPCN | Lipocine | PairCorr |
| 0.33 | ADAG | Adagene | PairCorr |
The ability to find closely correlated positions to RenovoRx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace RenovoRx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back RenovoRx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling RenovoRx to buy it.
The correlation of RenovoRx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as RenovoRx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if RenovoRx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for RenovoRx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for RenovoRx Stock Analysis
When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.